HC Wainwright Comments on Scholar Rock Q3 Earnings

Scholar Rock Holding Co. (NASDAQ:SRRK) – Analysts at HC Wainwright issued their Q3 2025 EPS estimates for shares of Scholar Rock in a research note issued on Tuesday, November 12th. HC Wainwright analyst A. Maldonado expects that the company will post earnings per share of ($0.68) for the quarter. HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.37) per share. HC Wainwright also issued estimates for Scholar Rock’s Q4 2025 earnings at ($0.62) EPS.

SRRK has been the topic of several other research reports. BMO Capital Markets upped their price objective on shares of Scholar Rock from $34.00 to $38.00 and gave the stock an “outperform” rating in a report on Friday, October 11th. Piper Sandler raised their price target on shares of Scholar Rock from $28.00 to $42.00 and gave the company an “overweight” rating in a research report on Tuesday, October 15th. JPMorgan Chase & Co. boosted their price objective on Scholar Rock from $18.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, October 14th. Finally, Wedbush restated an “outperform” rating and issued a $37.00 target price on shares of Scholar Rock in a report on Monday, November 4th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $34.00.

Scholar Rock Stock Up 2.7 %

Shares of NASDAQ SRRK opened at $27.38 on Thursday. The company’s fifty day simple moving average is $19.86 and its 200 day simple moving average is $13.43. The firm has a market cap of $2.19 billion, a PE ratio of -11.65 and a beta of 0.47. The company has a quick ratio of 6.04, a current ratio of 6.04 and a debt-to-equity ratio of 0.36. Scholar Rock has a 12-month low of $6.76 and a 12-month high of $35.38.

Insider Transactions at Scholar Rock

In related news, CFO Edward H. Myles sold 206,240 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $26.56, for a total value of $5,477,734.40. Following the sale, the chief financial officer now directly owns 161,088 shares in the company, valued at approximately $4,278,497.28. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CFO Edward H. Myles sold 206,240 shares of the stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $26.56, for a total transaction of $5,477,734.40. Following the sale, the chief financial officer now owns 161,088 shares of the company’s stock, valued at approximately $4,278,497.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Srinivas Akkaraju sold 1,175,713 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $29.25, for a total value of $34,389,605.25. Following the sale, the director now owns 5,612,896 shares in the company, valued at approximately $164,177,208. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,415,340 shares of company stock worth $40,666,088 in the last quarter. Insiders own 19.20% of the company’s stock.

Institutional Investors Weigh In On Scholar Rock

Large investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Scholar Rock by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company’s stock valued at $25,000 after buying an additional 514 shares in the last quarter. Principal Financial Group Inc. purchased a new stake in Scholar Rock during the second quarter valued at about $98,000. Hsbc Holdings PLC bought a new stake in Scholar Rock during the second quarter worth about $100,000. Point72 DIFC Ltd purchased a new position in shares of Scholar Rock in the 2nd quarter worth about $103,000. Finally, Creative Planning bought a new position in shares of Scholar Rock during the 3rd quarter valued at about $115,000. Institutional investors own 91.08% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.